Future  of AI in the Pharmaceutical Industry conference

'What is the future of AI in pharma?' - discussed by Prof Richard Barker, Dr Alex Aliper, Prof Li Su  and Prof Conrad Bessant

H﻿ow will Artificial Intelligence shape the future of the pharmaceutical industry? Discussed by Insilico Medicine co-founder Alex Aliper; Prof Li Su, head of the Artificial Intelligence and Computational Neuroscience group at the University of Cambridge; Prof Richard Barker, Founding Director of Metadvice and Visiting Professor of Precision Population Health at King&#x27;s College London and Prof Conrad Bessant, Professor of Bioinformatics at Queen Mary, University of London. T﻿he event will consist of four talks, followed by a discussion and time for questions at the end. T﻿his event will take place via Zoom, you will receive the Zoom link per email one day before the event.AI for Drug Discovery: Everything Everywhere All at OnceProf Conrad Bessant, Queen Mary University of LondonThe field of drug discovery offers a plethora of interesting multidisciplinary research problems. While the general aim of getting better therapeutics to patients faster is clear, the many steps underpinning this process involve a wide range of data types, from genomics and other -omic data through to medical images, chemical structures, electronic health records and unstructured free text. These data demand an equally diverse range of computational methods such as machine learning, Bayesian statistics, network science, computer vision, natural language processing, automated reasoning and generative AI. To illustrate current work in AI for Drug Discovery, this talk will briefly showcase some projects from the Bessant Lab and from the wider AIDD doctoral training programme hosted at QMUL’s Digital Environment Research Institute.Generative AI and 6th Generation Drug Discovery Robotics for Chemistry, Biology and MedicineD﻿r Alex Aliper, Co-founder and president of Insilico MedicineAbstract: Drug discovery and development has proven to be a notoriously challenging undertaking with a high failure rate and an average cost of $1 billion to advance from the discovery stages to market. Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation generative AI systems. Working with pharmaceutical and academic partners, Insilico seeks to accelerate and improve drug discovery and development efforts with an end-to-end, validated Pharma.AI platform by decreasing costs and increasing the probability of success.Pharma.AI utilizes deep generative models, reinforcement learning, transformers, and other modern machine-learning techniques to discover novel targets and design novel molecular structures with desired properties. Drawing on trillions of data points, the platform has three distinct but interconnected software solutions leveraging the power of generative AI – novel target discovery (PandaOmics), novel drug design (Chemistry42), and clinical trial outcome prediction (InClinico).A real-world interconnected expansion of Insilico&#x27;s end-to-end AI-driven drug discovery platform is a newly launched fully autonomous AI-run robotics lab that performs experiments, captures data, and further validates its AI-discovered and designed drugs. Playing a meaningful role in the future of drug discovery using AI and robotics, Insilico&#x27;s goal is to facilitate a precision medicine future and accelerate global drug discovery and development to provide new treatment options to patients.

Our {communityGuidelinesLink} describe the sort of content we prohibit on 91����. If you suspect an event may be in violation, you can report it to us so we can investigate.

To report other categories of prohibited or illegal content, submit {link}

91��

Future of AI in the Pharmaceutical Industry conference

More events from this organiser

Follow organisers to get events picked for you

Still looking for the right event?

Explore all online events to browse and filter by date, category, and more.

91����